30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.
The aim of this study was to model in mice the association between metabolic syndrome and the administration of atypical antipsychotic (AAP). Two dosages (4 and 8 mg/kg per day) of olanzapine (OL) were infused in 36 female mice for 30 days by osmotic mini-pumps. This study was also designed to further extend the implications raised in other experiments by our model of AAP-induced metabolic dysregulation. Through the use of the osmotic mini-pumps, this model is aimed to circumvent the shorter (than in humans) half-life of AAPs in rodents and to chronically administer OL by a reliable and less disturbing method. Indirect calorimetry was used to evaluate metabolic rate (MR) and respiratory exchange ratio together with weight and caloric intake. Serum insulin, leptin, and glucose tolerance (oral glucose tolerance test) were assessed. Pancreatic beta cells insulin levels, periuterine and liver fat content were also analyzed. Olanzapine-infused mice exhibited a reduction of overall MR (kilojoule per hour) and resting MR and respiratory exchange ratio, with periuterine fat significantly enlarged. All metabolic alterations were detected at the highest dose, with major effects found on weight gain and hyperphagia. Impaired glucose metabolism, associated with hyperinsulinemia and hyperleptinemia were found. Insulin resistance was evidenced by the raise of HOMA-IR index. Increased insulin and lipid storage were detected at pancreatic and hepatic levels respectively. These findings illustrate the development of a cluster of risk factors (metabolic syndrome) and, for the first time, a decrease of energy expenditure (MR) due to chronic OL infusion.
Coccurello
Roberto
R
Institute of Neuroscience, National Research Council, Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Rome; Italy.
Brina
Daniela
D
Caprioli
Antonio
A
Conti
Roberto
R
Ghirardi
Orlando
O
Schepis
Filippo
F
Moles
Anna
A
D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D050171:Dyslipidemias / Q000097:blood* / Q000139:chemically induced; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood* / Q000139:chemically induced; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D007333:Insulin Resistance / Q000502:physiology*; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced; D051379:Mice; D000077152:Olanzapine; D013997:Time Factors
D001569:Benzodiazepines; D000077152:Olanzapine